Navigation Links
Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
Date:9/8/2011

ch differ by only two nucleotides, are intronic microRNAs located within the sterol response element binding protein genes SREBF2 and SREBF1, respectively, which code for transcription factors that regulate cholesterol and fatty acid metabolism. Recent studies have shown that miR-33a/b regulates the cholesterol and fatty acid pathways in a negative feedback loop.  miR-33/b represses the cholesterol transporter ABCA1 resulting in decreased cellular cholesterol efflux to HDL-C and reverse cholesterol transport. Inhibition of miR-33 in mice, which only have miR-33a, resulted in enhanced cholesterol transport and reduction of atherosclerotic plaques (Rayner et al., J Clin Invest doi:10.1172/JCI57275). miR-33a/b also suppresses key enzymes involved in the oxidation of fatty acids resulting in the accumulation of triglycerides. Inhibition of miR-33a/b increases fatty acid oxidation and insulin signaling (Davalos et al., PNAS doi:10.1073/pnas.1102281108). These studies suggest that an anti-miR33a/b oligonucleotide treatment may be a promising strategy to treat metabolic disease.  

miR-21.  Regulus is developing microRNA therapeutics targeting miR-21 using proprietary chemically modified anti-miR oligonucleotides delivered systemically. Recent studies have demonstrated that miR-21 is overexpressed in many cancer types (Volinia et al., PNAS. 2006) and can promote tumor progression and metastasis (Medina et al., Nature. 2010). Regulus data has shown that miR-21 is upregulated in patients with hepatocellular carcinoma (HCC). In preclinical models of HCC, short term treatment (2-3 weeks) with anti-miR-21 inhibited miR-21 in the liver and reduced liver tumor formation. Longer term treatment (17 weeks) with anti-miR-21 resulted in a significant survival advantage (p<0.0001) over saline and control anti-miR treated mice. These findings suggest that miR-21 is a promising target for cancer.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
2. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
(Date:7/10/2014)... 10, 2014  BC Technical, the largest nationwide, non-OEM ... , Inc., a leading provider of Siemens Nuclear Medicine ... agreement naming BC Technical as the authorized provider of ... MiE and BC Technical announced today that the two ... Technical as the service and systems provider for MiE,s ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Calif., June 2, 2011 DURECT Corporation (Nasdaq: ... Chief Medical Officer and Executive Vice President, Corporate Strategy ... opportunities.  Dr. Stauffer and DURECT have entered into a ... (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO ) "We appreciate all ...
... SAN DIEGO, June 2, 2011 Biocept, Inc. today ... a poster at the 2011 Annual Meeting of the ... Chicago, Illinois June 3-7. The poster presentation is based ... logy C ell E nrichment and ...
Cached Medicine Technology:DURECT Announces Resignation of Chief Medical Officer 2Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) 2Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs) 3
(Date:7/11/2014)... 2014 The Europe Well Intervention Market report ... with analysis and revenue forecast. The well intervention services market ... in 2013 to $3.4 billion by 2018, at a CAGR ... TOC of the Europe Well Intervention Market report, to get ... a glimpse of the segmentation in the Europe well intervention ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... (HealthDay News) -- U.S. health officials have concluded that ... live anthrax during a safety mishap last month. ... officials have announced a moratorium on the transfer of ... In a report issued Friday, the CDC outlined ... a similar incident doesn,t occur again. Last month, as ...
(Date:7/11/2014)... CT (PRWEB) July 11, 2014 ... the nation’s only non-profit dedicated exclusively to cell ... that Joshua Corday has joined the organization as ... fundraising professional with deep experience securing gifts and ... served as Annual Giving Director for NewYork Presbyterian ...
(Date:7/11/2014)... July 11, 2014 Biostimulants are widely ... in turf and ornamentals. These also help turf and ... length of roots. Turf, ornamentals, and flowers appear healthy ... this usage has increased from the last few years. ... and ornamentals is Europe, with around 40% share in ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
... 6 percent of U.S. hospital emergency departments are fully ... of novel H1N1 (swine) flu expected this winter, the ... In a joint policy statement published in Pediatrics ... Department," pediatric emergency medicine specialists and others provide recommendations ...
... Federal stimulus funding is helping a Kansas State University ... Their research is creating a clearer picture of a ... chronic diseases like cancer. Katsura Asano, K-State associate ... from the National Institutes of Health,s National Institute of ...
... so-called junk DNA to be cut and pasted within genetic ... therapies. The study by researchers at the University of ... in which shifted genes have a significant effect on the ... antibody genes can enable the immune system to target infection ...
... NEW YORK, Sept. 21 Within the first three seconds ... in many first encounters, from the first day of school to the ... help you exude confidence, so follow these helpful tips to get yourself ... go to: http://www.prnewswire.com/mnr/crest/39172/ , , ...
... INDIANAPOLIS, Sept. 21 Eli Lilly and Company ... on the Human Rights Campaign,s (HRC) Corporate Equality Index for 2010. ... the Best Places to Work for Lesbian, Gay, Bisexual, and Transgender (LGBT) ... organization,s efforts related to creating an equitable environment for lesbian, gay, bisexual, ...
... , , ABBOTT PARK, Ill., Sept. 21 ... from the U.S. Food and Drug Administration (FDA) for its ABBOTT PRISM ... HIV-1/HIV-2. This test can be used by laboratory professionals to screen ... type 1 Groups M and O (anti-HIV-1) and type 2 (anti-HIV-2), and ...
Cached Medicine News:Health News:Photos: Fall's First Impressions 2Health News:Lilly Receives 100 Percent Rating on Corporate Equality Index Survey 2Health News:Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2 2Health News:Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2 3
... In the specialty areas of ... intensive care work, it is ... your practice. Alokas motorized TEE ... and Tissue Harmonic Echo technology ...
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... The 5548 is our High Penetration ... frequencies ranging from 3 to 8 MHz. ... transducer, offering Pure Harmonic Detection with 4 ... superficial or deeper vessels. The high color ...
... The UST-MC11-8731 is a perfect alternative ... are used to seeing more of a ... of the transducer in the hand., This ... shaped convex intraoperative transducer. The UST-MC11-8731 nestles ...
Medicine Products: